심장 폐쇄 기기 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Heart Closure Devices Market, valued at USD 4 billion in 2024, is expected to grow at a robust CAGR of 15.9% from 2025 to 2034. This growth can be attributed to the rising prevalence of cardiovascular diseases, a shift towards minimally invasive procedures, and improved reimbursement policies, among other factors.

Cardiovascular diseases (CVDs) remain a leading global health issue, contributing to millions of deaths annually. The aging population, increasing lifestyle-related risk factors, and sedentary living have propelled the demand for heart closure devices. These devices are becoming essential in treating heart defects effectively and are seen as an ideal solution for many patients due to their minimally invasive nature.

The demand for heart closure devices is fueled by their ability to offer a less invasive alternative to traditional surgeries. These devices are typically inserted via catheter-based procedures and allow patients to recover faster with less pain and fewer hospital stays compared to conventional open-heart surgeries. As patients and healthcare providers increasingly opt for minimally invasive treatments, the heart closure devices market is growing steadily.

Heart closure devices are used to close abnormal heart openings, particularly atrial and ventricular septal defects, which are congenital conditions. These defects cause unintended blood flow between the heart's chambers. In terms of product type, the market is divided into categories such as left atrial appendage (LAA) closure devices, atrial septal defect (ASD) closure devices, ventricular septal defect (VSD) closure devices, and patent foramen ovale (PFO) closure devices, with LAA devices leading the market due to their numerous benefits.

LAA closure devices are particularly effective in reducing stroke risk and offer an alternative to long-term anticoagulant therapy, which can cause complications. These devices are increasingly preferred for their low complication rates, faster recovery, and reduced hospital stays, leading to a higher adoption rate. Technological advances and increased awareness are also driving the growing use of LAA devices.

In terms of material, nitinol-based heart closure devices are expected to lead market growth, owing to their superelasticity and excellent biocompatibility. These devices are compressed into catheters for less invasive procedures and perform well under the dynamic forces within the heart, ensuring long-term patient safety. The growing need for reliable cardiovascular solutions is driving the demand for these devices, with the market projected to reach over USD 9.2 billion by 2034.

The transcatheter delivery method, which is less invasive than traditional surgery, is another key growth driver in the heart closure devices market. With transcatheter procedures, patients experience fewer complications and a faster recovery time, making it a popular choice among both healthcare providers and patients. As transcatheter technologies continue to improve, the market share for these devices is expected to grow significantly.

In terms of end-use, hospitals dominate the market due to their advanced facilities and expertise in handling complex heart closure procedures. The presence of skilled medical professionals ensures that patients receive the highest standard of care, further reinforcing hospitals' market leadership.

North America leads the global market for heart closure devices, with a projected CAGR of 14.3% from 2025 to 2034. The region's early adoption of innovative technologies, coupled with favorable reimbursement policies and substantial investments in research, further supports its dominance in the heart closure devices market.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of cardiovascular diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Rising preference for minimally invasive procedures
    • 3.2.1.4 Favorable reimbursement policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory policies
    • 3.2.2.2 Potential complications and adverse events
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Reimbursement scenario
• 3.6 Pricing analysis, 2023
• 3.7 Technology landscape
• 3.8 Future market trends
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn, Units)

• 5.1 Key trends
• 5.2 Atrial Septal Defect (ASD) Closure devices
• 5.3 Ventricular Septal Defect (VSD) Closure devices
• 5.4 Patent Foramen Ovale (PFO) Closure devices
• 5.5 Left Atrial Appendage (LAA) Closure devices
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By Material, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Nitinol-based devices
• 6.3 Stainless steel devices
• 6.4 Other materials

Chapter 7 Market Estimates and Forecast, By Mode of Delivery, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Transcatheter delivery
• 7.3 Surgical delivery

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory Surgical Centers (ASCs)
• 8.4 Cardiac catheterization laboratories
• 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn, Units)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AtriCure
• 10.3 Biosense Webster
• 10.4 Boston Scientific Corporation
• 10.5 Cardia
• 10.6 Heartstitch
• 10.7 Lepu Medical Technology (Beijing)Co., Ltd.
• 10.8 LifeTech Scientific Corporation
• 10.9 Medtronic
• 10.10 Occlutech
• 10.11 SentreHEART
• 10.12 Starway Medical Technology
• 10.13 W. L. Gore & Associates